Case ReportsResponse to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer
Under an Elsevier user license
open archive
Cited by (0)
Disclosure: Dr. Weickhardt has received honoraria from Pfizer. Dr. Camidge has acted as a consultant for Pfizer at ad hoc advisory boards. The other author declares no conflict of interest.
Copyright © 2013 International Association for the Study of Lung Cancer. All rights reserved.